Core Insights - The article highlights the entrepreneurial journey of Li Yi, who founded Nanjing Pet Medicine Technology Co., Ltd. (派特美生) focusing on innovative pet pharmaceuticals, driven by personal experiences and market opportunities [1][2]. Company Overview - Nanjing Pet Medicine Technology Co., Ltd. was established in August 2023, aiming to develop innovative drugs for pets, leveraging Li Yi's extensive background in human pharmaceuticals [1][2]. - The company has developed a pet drug screening platform, the first of its kind in China, through collaboration with universities and research institutions [3]. Market Opportunity - The pet healthcare market in China is relatively untapped compared to human pharmaceuticals, with no leading Chinese companies in the global pet medicine sector [2]. - Li Yi's vision is to position the company as a pioneer in the pet pharmaceutical industry, similar to the advancements seen in human medicine [2][5]. Product Development - The company has introduced a pet endoscope, which allows for non-invasive retrieval of foreign objects from pets, and a soft chewable medication platform that makes administering medicine more appealing to pets [3]. - The soft chewable platform has shown promising results in palatability tests, particularly for dogs, while still facing challenges with cats due to their unique eating habits [3]. Financial Aspects - The company started with a registered capital of over 5 million yuan, backed by three publicly listed companies, but faced rapid cash burn during the initial research and development phase [4]. - After overcoming initial financial challenges with angel investment and support from local government policies, the company is now on a stable growth trajectory [5]. Future Goals - Li Yi aims to lead Nanjing Pet Medicine Technology Co., Ltd. to become a global leader in the pet healthcare sector, increasing the representation of "Made in China" products in the global pet pharmaceutical market [5].